USD 2.50 Billion
Retinal Disorder Treatment Market Size, Share, Growth Analysis, By Type(Macular Degeneration (Dry Macular Degeneration, Wet Macular Degeneration), Diabetic Retinopathy, Others), By Dosage Form(Gels, Eye Solutions, Capsules & Tablets, Eye Drops), By Distribution Channel(Hospital, Online, Retail), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35I2302 |
Region:
Global |
Published Date: August, 2024
Pages:
219
|Tables:
67
|Figures:
80
Retinal Disorder Treatment Market Insights
Retinal Disorder Treatment Market size was valued at USD 2.50 Billion in 2022 and is poised to grow from USD 2.71 Billion in 2023 to USD 5.21 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).
The global retinal disorder treatment market is a dynamic and rapidly evolving sector within the healthcare industry, focused on diagnosing and managing various retinal conditions that affect vision. This overview provides a concise summary of key trends and factors influencing the market. Retinal disorders, such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, are becoming increasingly prevalent due to aging populations and rising diabetes rates.
These conditions can lead to vision impairment or even blindness if left untreated, driving the demand for effective treatment options. One of the most significant developments in the market is the advent of novel therapies, including anti-VEGF drugs, gene therapies, and stem cell therapies. Anti-VEGF drugs, such as Lucentis and Eylea, have revolutionized the treatment landscape for wet AMD and diabetic retinopathy, offering patients improved outcomes and convenience through intravitreal injections. Gene therapies hold promise for addressing certain inherited retinal disorders, offering the potential for long-lasting or even permanent vision improvement.
Advancements in retinal imaging technologies, including optical coherence tomography (OCT) and fundus photography, have enhanced the diagnosis and monitoring of retinal disorders, enabling earlier intervention and more personalized treatment approaches. While these innovations are driving market growth, challenges include the high cost of treatment and the need for ongoing monitoring and management. Additionally, regulatory and reimbursement considerations can impact the adoption of new therapies. In conclusion, the global retinal disorder treatment market is characterized by innovation and growth opportunities, fueled by an aging population and increasing prevalence of retinal conditions.
As research and development efforts continue to expand, the market is likely to witness further advancements in diagnosis and treatment, improving the quality of life for individuals affected by retinal disorders.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Macular Degeneration
Fastest Growth
Macular Degeneration
Growth Rate
8.50% CAGR
Retinal Disorder Treatment Market ($ Bn)
Country Share North America for Region (%)
To get more reports on the above market click here to Buy The Report
Retinal Disorder Treatment Market Segmental Analysis
The global retinal disorder treatment market is segmented on the basis of type, dosage form, distribution channel and region. By type, the market is segmented into Macular Degeneration (Dry Macular Degeneration, Wet Macular Degeneration), Diabetic Retinopathy, and Others. By dosage form, the market is segmented into gels, eye solutions, capsules & tablets, eye drops, and ointments. By distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Analysis By Type
In the global retinal disorder treatment market, the dominant segment is the Macular degeneration, particularly age-related macular degeneration (AMD), due to its high prevalence among the aging population. AMD is a leading cause of vision loss, and as the global population ages, the incidence of this condition is expected to rise. This has led to a growing demand for treatments and therapies to manage and treat macular degeneration, including both dry and wet forms.
On the other hand, the fastest-growing segment in the global retinal disorder treatment market is the Diabetic retinopathy. The increasing prevalence of diabetes globally, especially in developing countries, has significantly contributed to the growth of diabetic retinopathy cases. Diabetic retinopathy can lead to vision impairment and blindness if not managed effectively. As awareness about diabetes and its ocular complications grows, more individuals are seeking early diagnosis and treatment for diabetic retinopathy. This has propelled the demand for retinal disorder treatments specific to diabetic retinopathy, including laser therapy, anti-VEGF drugs, and vitrectomy.
Analysis By Dosage Form
In the global retinal disorder treatment market, Eye solutions, which include liquid medications administered directly to the eye, are the dominant segment. They are widely used for the treatment of various retinal disorders, including macular degeneration and diabetic retinopathy. Eye solutions offer advantages such as precise dosing and rapid absorption into the eye, making them a preferred choice for ophthalmologists and patients. These solutions often contain essential medications like anti-VEGF drugs, steroids, or antibiotics to manage retinal conditions effectively. The dominance of this segment can be attributed to the ease of administration and the targeted delivery of medication to the affected area.
On the other hand, the fastest-growing segment in the global retinal disorder treatment market is Capsules & Tablets segment is experiencing the fastest growth within the retinal disorder treatment market. While eye solutions dominate due to their localized action, capsules and tablets are gaining traction for their systemic approach in treating retinal disorders. Medications in the form of capsules or tablets are designed to address underlying retinal conditions by targeting systemic factors such as inflammation or blood vessel abnormalities. The growth of this segment is driven by the development of innovative oral medications and the increasing recognition of the systemic aspects of retinal disorders. Patients prefer the convenience of oral medication, and pharmaceutical companies are investing in research and development to bring effective retinal disorder treatments in this dosage form to the market.
Retinal Disorder Treatment Market By Type
To get detailed analysis on other segments, Request For Free Sample Report
Retinal Disorder Treatment Market Regional Insights
The global retinal disorder treatment market is analyzed based on its regional presence, which includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America, specifically the United States, is a dominant region in the global retinal disorder treatment market. This dominance is attributed to factors such as a well-established healthcare infrastructure, high healthcare expenditure, a large patient pool suffering from retinal disorders like age-related macular degeneration (AMD) and diabetic retinopathy, and a strong presence of leading pharmaceutical and biotechnology companies specializing in retinal disorder treatments. Additionally, the region benefits from extensive research and development activities, advanced diagnostic technologies, and early adoption of innovative therapies.
On the other hand, Asia-Pacific is emerging as the fastest-growing region in the global retinal disorder treatment market. The Asia-Pacific region, including countries like China, India, Japan, and South Korea, is experiencing rapid growth in the retinal disorder treatment market. This growth is primarily driven by a rising aging population, increasing prevalence of diabetes (a major risk factor for retinal disorders), improving healthcare infrastructure, and growing awareness about retinal diseases and their treatment options. As the middle-class population expands in these countries, there is a greater ability to access healthcare services and advanced treatments, contributing to the significant growth potential of the retinal disorder treatment market in the Asia-Pacific region.
Retinal Disorder Treatment Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Retinal Disorder Treatment Market Dynamics
Drivers
Aging Population:
- The aging population is a significant driver of the retinal disorder treatment market. As people age, they become more susceptible to various eye conditions, including age-related macular degeneration (AMD) and diabetic retinopathy. With a growing elderly population globally, the prevalence of retinal disorders is expected to increase, driving demand for retinal disorder treatments and therapies.
Technological Advancements:
- Advances in ophthalmic technology and treatment options have been driving the retinal disorder treatment market. Innovations such as anti-VEGF (vascular endothelial growth factor) therapies and the development of advanced retinal imaging techniques have improved the diagnosis and management of retinal disorders. These technological advancements offer more effective and less invasive treatment options, which can lead to better outcomes for patients.
Restraints
High Treatment Costs:
- The cost of retinal disorder treatments can be a significant restraint on the market. Many treatments, including anti-VEGF therapies and surgical procedures, can be expensive. This high cost can limit access to treatment for some patients, particularly in regions with limited healthcare resources or where insurance coverage is not comprehensive.
Limited Availability of Specialized Healthcare Professionals:
- Retinal disorder treatments often require the expertise of specialized ophthalmologists and retinal surgeons. In some areas, there may be a shortage of healthcare professionals with the necessary skills and training to diagnose and treat retinal disorders effectively. This limitation in the availability of specialized healthcare providers can impede timely access to treatment for patients.
Request Free Customization of this report to help us to meet your business objectives.
Retinal Disorder Treatment Market Competitive Landscape
The global retinal disorder treatment market is characterized by intense competition among pharmaceutical companies, medical device manufacturers, and research institutions. Key players include Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holdings AG, and Allergan Plc. These companies are engaged in extensive research and development activities to introduce innovative treatments and therapies for retinal disorders, such as age-related macular degeneration and diabetic retinopathy. Collaborations, partnerships, and mergers and acquisitions are common strategies employed to strengthen market presence and expand product portfolios. For instance, Novartis acquired Alcon, a leading eye care company, to enhance its ophthalmic product offerings. Technological advancements in drug delivery systems and the development of gene therapies have become key competitive factors. Companies like Spark Therapeutics, now a subsidiary of Roche, have gained prominence for their pioneering work in gene therapies for inherited retinal disorders. Market players also focus on expanding their geographical reach through global distribution networks and strategic alliances with healthcare providers and institutions. Overall, the competitive landscape in the global retinal disorder treatment market is marked by innovation, strategic partnerships, and a commitment to addressing the unmet medical needs of patients with retinal disorders.
Top Player’s Company Profile
- Novartis (Switzerland)
- Roche (Switzerland)
- Regeneron Pharmaceuticals (USA)
- Genentech (USA)
- Allergan (Ireland)
- Bausch Health Companies (Canada)
- Alimera Sciences (USA)
- Ophthotech Corporation (USA)
- Spark Therapeutics (USA)
- Kodiak Sciences (USA)
- Santen Pharmaceutical (Japan)
- Bayer AG (Germany)
- Regenxbio (USA)
- Chengdu Kanghong Pharmaceutical Group (China)
- Graybug Vision (USA)
- Apellis Pharmaceuticals (USA)
- Adverum Biotechnologies (USA)
- Clearside Biomedical (USA)
- Acucela Inc. (USA)
- PanOptica, Inc. (USA)
- Opthea Limited (Australia)
- Oxurion NV (Belgium)
- Kala Pharmaceuticals (USA)
- Hemera Biosciences (USA)
- Tyrogenex (USA)
Recent Developments
- In May 2023, Roche announced that its anti-VEGF drug Lucentis had been approved by the US Food and Drug Administration (FDA) for the treatment of central retinal vein occlusion (CRVO). Lucentis is the first anti-VEGF drug to be approved for the treatment of CRVO in the US.
- In June 2023, Genentech announced that its bispecific antibody RG6206 had met its primary endpoint in a Phase 2 clinical trial for the treatment of diabetic macular edema (DME). RG6206 is designed to block both VEGF-A and angiopoietin-2, two key drivers of DME.
- In July 2023, Bayer announced that it had acquired Vividion Therapeutics, a company developing gene therapies for retinal diseases. This acquisition gives Bayer access to Vividion's pipeline of gene therapy candidates for RP, choroideremia, and other retinal disorders.
Retinal Disorder Treatment Key Market Trends
-
Advancements in Retinal Imaging and Diagnostic Technologies: There has been significant progress in retinal imaging and diagnostic technologies. Advanced imaging techniques, such as optical coherence tomography (OCT) and adaptive optics, have improved the ability to detect and diagnose retinal disorders at earlier stages. This early detection is critical for initiating timely treatment and preventing further vision loss. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into retinal imaging has enhanced the accuracy and efficiency of diagnosis, making it easier for healthcare providers to identify and treat retinal disorders.
-
Rise in Biologic and Gene Therapy Approaches: The treatment landscape for retinal disorders has been evolving with the development of biologic and gene therapy approaches. These innovative treatments aim to address the underlying genetic causes of certain retinal disorders, such as retinitis pigmentosa and Leber congenital amaurosis. Gene therapy, in particular, has shown promise in clinical trials and received regulatory approvals for some specific conditions. These therapies have the potential to provide long-term benefits by correcting or mitigating the genetic defects responsible for retinal diseases, offering hope to patients with previously untreatable conditions.
Retinal Disorder Treatment Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Component types team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global retinal disorder treatment market analysis, the market is witnessing substantial growth driven by several key factors within the healthcare and pharmaceutical industries. This analysis provides a concise overview of the critical trends and factors shaping this market. One of the primary drivers of the retinal disorder treatment market is the rising prevalence of retinal diseases, particularly age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. The aging global population and the increasing incidence of diabetes contribute significantly to the growing patient pool requiring treatment. Technological advancements in retinal disorder treatment options, including the development of innovative drugs, gene therapies, and advanced surgical techniques, have expanded the treatment landscape. These innovations offer more effective and less invasive solutions, improving patient outcomes and quality of life. The market also benefits from increased awareness and early diagnosis of retinal disorders, leading to a higher demand for treatment interventions. Additionally, government initiatives and healthcare reforms aimed at addressing retinal disorders further stimulate market growth. However, challenges in the market include the high cost of some treatment modalities, limited access to specialized healthcare services in certain regions, and regulatory hurdles associated with drug approvals. In conclusion, the global retinal disorder treatment market is on a growth trajectory due to demographic changes, technological advancements, and increased awareness. As the prevalence of retinal diseases continues to rise, the market is expected to see sustained expansion with a focus on affordability and accessibility to meet the growing demand for effective treatments.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 2.50 Billion |
| Market size value in 2031 | USD 5.21 Billion |
| Growth Rate | 8.50% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Retinal Disorder Treatment Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Retinal Disorder Treatment Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Retinal Disorder Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Retinal Disorder Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Retinal Disorder Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Retinal Disorder Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
